DDrare: Database of Drug Development for Rare Diseases

94. 原発性硬化性胆管炎
［臨床試験数：134，薬物数：105（DrugBank：37），標的遺伝子数：18，標的パスウェイ数：131］

Searched query = "Primary sclerosing cholangitis", "PSC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 11C-CSar; 3108006977; ACETYLCYSTEINE; ACIDO OBETICOLICO; ATRA; AZT; Acetylcysteine; All-trans retinoic acid; Azathioprine; BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée; BEZAFIBRATE; BTT1023; BTT1023 IV Infusion 20 mg/mL, 5 mL Drug Product; Befizal; Bezafibrate; Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy; Bezalip; Budesonide; C10AB02; CILO; CM-101; Calcium; Capecitabine; Cenicriviroc; Cenicriviroc 150 mg; Cilofexor; Cis-4-Hydroxy-L-Proline; Cladribine; Curcumin; DHA; DUR-928; Docosahexaenoic Acid (DHA); Docosahexaenoic acid; Engineered recombinant human FGF19; Entyvio; Erlotinib; Erlotinib (Tarceva); FLUIMUCIL*20CPR EFF 600MG; Fecal Microbiota Transplantation; Fenofibrate; Fluimucil; GS-6624; GS-9674; Gluten-free diet; HTD1801; Humanised IgG1 monoclonal antibody against human eotaxin-2; Hymecromone; ICG; INT-747, OCA; LUM001; MBX-8025; MLN0002; Metronidazole; Minocycline; Mitomycin; Mitomycin C; Mizoribine; NGM282; NorUDCA; NorUrsodeoxycholic Acid; NorUrsodeoxycholic acid; Normal saline; Norursodeoxycholic acid; OCA; OCA 1,5 mg; OCA 5 mg; Oral Vancomycin; Oral all-trans retinoic acid (ATRA); Orbcel-C; PLN-74809; Phenylbutyrate; Probiotics; Procedure: Liver transplantation; Procedure: Pre liver transplantation laparoscopic hand assisted staging; Proline; Radiation: 45 Gy external radiations; Radiation: Endoluminal bile duct Brachytherapy; Rec-h-FGF19; Retinoic acid; Rituximab; SELADELPAR; Seladelpar; Simtuzimab; Simtuzumab; Simvastatin; Simvastatin 40mg; Sulfasalazine; TBC; Thalidomide; UCMSC; UDCA; Ursodeoxycholic Acid; Ursodeoxycholic acid; Ursodeoxycholic acid (UDCA); Ursofalk; Ursolic acid; VEDOLIZUMAB; Vancomycin; Vedolizumab; Vedolizumab IV; Vidofludimus; Vidofludimus calcium; Volixibat; Xifaxan; [18F]FP-R01-MG-F2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03046901 (ClinicalTrials.gov)	December 7, 2016	31/1/2017	Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients	Oral Vancomycin Treatment in Recurrent Primary Sclerosing Cholangitis in Liver Transplant Recipients	Primary Sclerosing Cholangitis;Post- Orthotopic Liver Transplantation	Drug: Vancomycin	Ochsner Health System	NULL	Withdrawn	N/A	N/A	All	0	N/A	United States
2	NCT02605213 (ClinicalTrials.gov)	September 2015	31/10/2015	Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients	Evaluation of Effectiveness and Safety of Oral Vancomycin in Treatment of Primary Sclerosing Cholangitis.	Primary Sclerosing Cholangitis	Drug: Vancomycin;Drug: Placebo	Tehran University of Medical Sciences	NULL	Recruiting	18 Years	60 Years	Both	30	Phase 4	Iran, Islamic Republic of
3	NCT01802073 (ClinicalTrials.gov)	January 2012	21/2/2013	Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects	Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects	Primary Sclerosing Cholangitis	Drug: Oral Vancomycin	Stanford University	NULL	Completed	1 Year	N/A	All	34	Phase 3	United States
4	NCT02137668 (ClinicalTrials.gov)	July 2010	12/5/2014	Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin	The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin	Primary Sclerosing Cholangitis;Biliary Atresia	Drug: Oral Vancomycin	Sacramento Pediatric Gastroenterology	NULL	Recruiting	N/A	40 Years	Both	200	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03046901
(ClinicalTrials.gov)

December 7, 2016

31/1/2017

Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients

Oral Vancomycin Treatment in Recurrent Primary Sclerosing Cholangitis in Liver Transplant Recipients

Primary Sclerosing Cholangitis;Post- Orthotopic Liver Transplantation

Drug: Vancomycin

Ochsner Health System

NULL

Withdrawn

N/A

All

N/A

United States

NCT02605213
(ClinicalTrials.gov)

September 2015

31/10/2015

Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients

Evaluation of Effectiveness and Safety of Oral Vancomycin in Treatment of Primary Sclerosing Cholangitis.

Primary Sclerosing Cholangitis

Drug: Vancomycin;Drug: Placebo

Tehran University of Medical Sciences

NULL

Recruiting

18 Years

60 Years

Both

Phase 4

Iran, Islamic Republic of

NCT01802073
(ClinicalTrials.gov)

January 2012

21/2/2013

Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

Primary Sclerosing Cholangitis

Drug: Oral Vancomycin

Stanford University

NULL

Completed

1 Year

N/A

All

Phase 3

United States

NCT02137668
(ClinicalTrials.gov)

July 2010

12/5/2014

Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

Primary Sclerosing Cholangitis;Biliary Atresia

Drug: Oral Vancomycin

Sacramento Pediatric Gastroenterology

NULL

Recruiting

N/A

40 Years

Both

200

Phase 1

United States